US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

13.75

+1.098.61%

Post-market: 13.65-0.1000-0.73%19:54 EDT

Volume:277.54K

Turnover:3.80M

Market Cap:409.59M

PE:-47.08

High:14.39

Open:12.61

Low:12.58

Close:12.66

52wk High:26.50

52wk Low:2.57

Shares:29.79M

Float Shares:11.41M

Volume Ratio:2.22

T/O Rate:2.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2921

EPS(LYR):-0.1152

ROE:-686.28%

ROA:-50.27%

PB:596.29

PE(LYR):-119.31

Loading ...

Overview Company News Filings

Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer

Turn Therapeutics Appoints Former Cdc Director Robert R. Redfield, M.d., as Chief Scientific Officer

THOMSON REUTERS

Novabridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

THOMSON REUTERS

Turn Therapeutics Says Mouse Study Shows GX-03 Cuts Dermatitis Severity 66%

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

Turn Therapeutics Raises $1.35M Through Private Placement

Turn Therapeutics Sells 135,000 Shares in Private Placement for $1.35 Million

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)

Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs

Turn Therapeutics Q2 FY26 Net Loss Widens to USD 5.85 Million

Turn Therapeutics Q2 EPS USD -0.2

THOMSON REUTERS

Press Release: Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Releases Corporate Deck Outlining GX-03 Topical Immunomodulator Program for Atopic Dermatitis

Turn Therapeutics CEO to Ring NASDAQ Closing Bell

Turn Therapeutics Shares Rise on Expanded Phase 2 Study for Eczema Treatment

Turn Therapeutics - Gx-3 Shows Clinically Meaningful Efficacy in Patients with Easi Scores 1.1 to 7

THOMSON REUTERS

Turn Therapeutics Announces Final Stage 2 Design and Data-driven Expansion of Gx-03 Phase 2 Program in Atopic Dermatitis

THOMSON REUTERS

Turn Therapeutics - no Treatment-related Serious Adverse Events or Tolerability Issues Reported

THOMSON REUTERS

Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data

Turn Therapeutics to Host Webcast on GX-03 Atopic Dermatitis Phase 2 Interim Analysis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/TTRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TTRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","market":"US","secType":"STK","nameCN":"Turn Therapeutics (Direct Listing)","latestPrice":13.75,"timestamp":1788984000000,"preClose":12.66,"halted":0,"volume":277536,"hourTrading":{"tag":"盘后","latestPrice":13.65,"preClose":13.75,"latestTime":"19:54 EDT","volume":710,"amount":9709.1709,"timestamp":1788998091348,"change":-0.1,"changeRate":-0.007273,"amplitude":0.007273},"delay":0,"changeRate":0.08609794628751974,"floatShares":11408100,"shares":29788000,"eps":-0.292051,"marketStatus":"Not Yet Opened","change":1.09,"latestTime":"09-09 16:00:00 EDT","open":12.61,"high":14.39,"low":12.58,"amount":3798052.961472,"amplitude":0.14297,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.292051,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789027200000},"marketStatusCode":0,"adr":0,"listingDate":1759896000000,"exchange":"NASDAQ","adjPreClose":12.66,"preHourTrading":{"tag":"盘前","latestPrice":12.65,"preClose":12.66,"latestTime":"09:21 EDT","volume":762,"amount":9529.607052,"timestamp":1788960108214,"change":-0.01,"changeRate":-0.00079,"amplitude":0.045},"postHourTrading":{"tag":"盘后","latestPrice":13.65,"preClose":13.75,"latestTime":"19:54 EDT","volume":710,"amount":9709.1709,"timestamp":1788998091348,"change":-0.1,"changeRate":-0.007273,"amplitude":0.007273},"volumeRatio":2.222108},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","floatShares":11408100,"roa":"-50.27%","roe":"-686.28%","lyrEps":-0.115242,"volumeRatio":2.222108,"shares":29788000,"dividePrice":0,"high":14.39,"amplitude":0.14297,"preClose":12.66,"low":12.58,"week52Low":2.5701,"pbRate":"596.29","week52High":26.5,"institutionHeld":0,"latestPrice":13.75,"eps":-0.292051,"divideRate":0,"volume":277536,"delay":0,"ttmEps":-0.292051,"open":12.61,"prevYearClose":3.94,"prevWeekClose":9.8,"prevMonthClose":9.6,"prevQuarterClose":7.3,"fiveDayClose":9.82,"twentyDayClose":10.22,"sixtyDayClose":6.045},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"TTRX","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2026-05-11","symbol":"TTRX","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTRX","date":"2026-09-08","current":-47.080818,"percent":0.519824,"low":-100.764104,"twenty":-53.465444,"median":-34.739892,"eighty":-27.147139,"high":-21.019642,"avg":-40.428376,"sd":15.937222,"marketCap":291922792},"quantilePoints":[{"date":"2025-10-10","current":-100.764104,"twenty":-95.944951,"median":-88.716222,"eighty":-81.487493,"marketCap":257809999},{"date":"2025-10-17","current":-61.772777,"twenty":-80.611283,"median":-71.301556,"eighty":-62.49565,"marketCap":158048738},{"date":"2025-10-24","current":-54.215469,"twenty":-75.594983,"median":-58.815569,"eighty":-54.127848,"marketCap":138712988},{"date":"2025-10-31","current":-57.391729,"twenty":-70.118673,"median":-57.391729,"eighty":-54.25928,"marketCap":146839608},{"date":"2025-11-07","current":-46.548635,"twenty":-64.664269,"median":-55.529784,"eighty":-49.111548,"marketCap":119097010},{"date":"2025-11-14","current":-44.796216,"twenty":-60.918473,"median":-54.215469,"eighty":-46.701972,"marketCap":114613358},{"date":"2025-11-21","current":-21.019642,"twenty":-57.501255,"median":-52.517813,"eighty":-44.182869,"marketCap":79796445},{"date":"2025-11-28","current":-27.302265,"twenty":-57.501255,"median":-48.301054,"eighty":-27.302265,"marketCap":103647044},{"date":"2025-12-05","current":-32.964383,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"marketCap":125142027},{"date":"2025-12-12","current":-24.897804,"twenty":-55.858362,"median":-45.508136,"eighty":-26.138816,"marketCap":94519037},{"date":"2025-12-19","current":-23.268976,"twenty":-55.63931,"median":-44.029532,"eighty":-25.595874,"marketCap":88335549},{"date":"2025-12-26","current":-23.036286,"twenty":-55.464068,"median":-42.496165,"eighty":-24.137684,"marketCap":87452193},{"date":"2026-01-02","current":-30.559922,"twenty":-54.828816,"median":-32.964383,"eighty":-24.075634,"marketCap":116014021},{"date":"2026-01-09","current":-36.066913,"twenty":-54.30309,"median":-35.136154,"eighty":-24.292811,"marketCap":136920100},{"date":"2026-01-16","current":-37.385488,"twenty":-54.149753,"median":-35.834223,"eighty":-24.680627,"marketCap":141925782},{"date":"2026-01-23","current":-36.687419,"twenty":-53.711649,"median":-35.834223,"eighty":-25.083956,"marketCap":139275715},{"date":"2026-01-30","current":-33.740015,"twenty":-52.638292,"median":-35.911787,"eighty":-25.45626,"marketCap":128086546},{"date":"2026-02-06","current":-28.698404,"twenty":-50.513483,"median":-35.446407,"eighty":-25.69184,"marketCap":108947177},{"date":"2026-02-13","current":-27.806427,"twenty":-48.322959,"median":-35.097373,"eighty":-25.925975,"marketCap":105560981},{"date":"2026-02-20","current":-26.371506,"twenty":-48.027239,"median":-33.584888,"eighty":-25.643857,"marketCap":100113622},{"date":"2026-02-27","current":-29.784289,"twenty":-47.359128,"median":-32.809256,"eighty":-25.86537,"marketCap":113069502},{"date":"2026-03-06","current":-26.21638,"twenty":-47.161981,"median":-31.723371,"eighty":-25.999203,"marketCap":99524718},{"date":"2026-03-13","current":-28.892312,"twenty":-46.395298,"median":-30.559922,"eighty":-26.076766,"marketCap":109683306},{"date":"2026-03-20","current":-26.604196,"twenty":-45.672425,"median":-29.706726,"eighty":-26.154329,"marketCap":100996977},{"date":"2026-03-27","current":-26.371506,"twenty":-45.1467,"median":-28.892312,"eighty":-26.154329,"marketCap":100113622},{"date":"2026-04-02","current":-24.160954,"twenty":-44.796216,"median":-28.775967,"eighty":-25.98369,"marketCap":91721745},{"date":"2026-04-10","current":-32.734315,"twenty":-44.029532,"median":-28.989266,"eighty":-26.061253,"marketCap":104556020},{"date":"2026-04-17","current":-31.894973,"twenty":-43.81048,"median":-29.784289,"eighty":-26.138816,"marketCap":101875096},{"date":"2026-04-24","current":-31.242152,"twenty":-42.496165,"median":-30.559922,"eighty":-26.21638,"marketCap":99789934},{"date":"2026-05-01","current":-34.415795,"twenty":-38.471374,"median":-30.882559,"eighty":-26.371506,"marketCap":109926804},{"date":"2026-05-08","current":-35.392229,"twenty":-38.238684,"median":-31.242152,"eighty":-26.371506,"marketCap":113045611},{"date":"2026-05-15","current":-31.212763,"twenty":-37.850868,"median":-31.242152,"eighty":-26.44907,"marketCap":119747920},{"date":"2026-05-22","current":-38.588913,"twenty":-38.045407,"median":-31.288782,"eighty":-26.44907,"marketCap":148046558},{"date":"2026-05-29","current":-41.228799,"twenty":-38.837373,"median":-31.468187,"eighty":-26.480095,"marketCap":158174492},{"date":"2026-06-05","current":-44.606299,"twenty":-41.306443,"median":-31.521933,"eighty":-26.518877,"marketCap":171132289},{"date":"2026-06-12","current":-45.499201,"twenty":-41.792847,"median":-31.925517,"eighty":-26.588683,"marketCap":174557914},{"date":"2026-06-18","current":-46.819144,"twenty":-43.898101,"median":-32.128124,"eighty":-26.604196,"marketCap":179621881},{"date":"2026-06-26","current":-52.952995,"twenty":-44.973973,"median":-32.641055,"eighty":-26.650734,"marketCap":203154432},{"date":"2026-07-02","current":-53.185927,"twenty":-45.699909,"median":-32.809256,"eighty":-26.681759,"marketCap":204048074},{"date":"2026-07-10","current":-68.40409,"twenty":-46.788086,"median":-33.107355,"eighty":-26.74381,"marketCap":262432632},{"date":"2026-07-17","current":-70.112251,"twenty":-47.348176,"median":-33.573656,"eighty":-26.867911,"marketCap":268986001},{"date":"2026-07-24","current":-73.606217,"twenty":-48.853305,"median":-34.461027,"eighty":-26.945474,"marketCap":282390619},{"date":"2026-07-31","current":-64.056043,"twenty":-51.501785,"median":-34.552888,"eighty":-26.992012,"marketCap":245751330},{"date":"2026-08-07","current":-74.615585,"twenty":-53.558617,"median":-35.327878,"eighty":-27.007525,"marketCap":286263064},{"date":"2026-08-14","current":-34.775161,"twenty":-54.193564,"median":-35.356755,"eighty":-27.085088,"marketCap":293710074},{"date":"2026-08-21","current":-33.646556,"twenty":-54.04617,"median":-35.233657,"eighty":-27.147139,"marketCap":284177901},{"date":"2026-08-28","current":-35.656885,"twenty":-53.776019,"median":-34.888704,"eighty":-27.147139,"marketCap":301157084},{"date":"2026-09-04","current":-35.515809,"twenty":-53.558617,"median":-34.775161,"eighty":-27.147139,"marketCap":299965562},{"date":"2026-09-08","current":-34.563548,"twenty":-53.465444,"median":-34.739892,"eighty":-27.147139,"marketCap":291922792}],"updateTime":1789022077649},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666385845","title":"Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666385845","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666385845?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:01","pubTimestamp":1788955309,"startTime":"0","endTime":"0","summary":"Turn Therapeutics names former CDC director Robert Redfield chief scientific officerTurn Therapeutics named former CDC Director Robert R. Redfield as chief scientific officer.Redfield brings more than","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL1CzFFt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666388615","title":"Turn Therapeutics Appoints Former Cdc Director Robert R. Redfield, M.d., as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666388615","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666388615?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA5K6PCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322598","title":"Novabridge Appoints Martin Dewhurst to Board of Directors as an Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322598","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322598?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA2YPVXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007","NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660123281","title":"Turn Therapeutics Says Mouse Study Shows GX-03 Cuts Dermatitis Severity 66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660123281","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660123281?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:03","pubTimestamp":1787227408,"startTime":"0","endTime":"0","summary":"Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%Turn Therapeutics reported newly published, peer-reviewed preclinical results for GX-03 in a mouse model of dermatitis-like i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL6RWQjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608144","title":"Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608144","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608144?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:01","pubTimestamp":1787058073,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) just unveiled an update. On October 8, 2025, Turn Therapeutics Inc. issued a warrant to GEM Yield Bahamas Limited...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-unregistered-cashless-warrant-share-issuance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-unregistered-cashless-warrant-share-issuance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GEM","LENZ","BK4139","TTRX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432706","title":"Turn Therapeutics Raises $1.35M Through Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432706?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:55","pubTimestamp":1787000113,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) just unveiled an update. On August 14, 2026, Turn Therapeutics Inc. entered into securities purchase agreements w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-raises-1-35m-through-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-raises-1-35m-through-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TTRX","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660328194","title":"Turn Therapeutics Sells 135,000 Shares in Private Placement for $1.35 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660328194","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660328194?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:16","pubTimestamp":1786997813,"startTime":"0","endTime":"0","summary":"Turn Therapeutics sells 135,000 shares in private placement for $1.35 millionTurn Therapeutics entered securities purchase agreements on Aug. 14, 2026 for a private placement of common stock.Accredite","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL7krVmR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166042","title":"Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166042","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166042?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:35","pubTimestamp":1786638932,"startTime":"0","endTime":"0","summary":"In a report released today, Rick Bienkowski from Ladenburg Thalmann & Co. maintained a Buy rating on Turn Therapeutics Inc, with a price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ladenburg-thalmann-co-keeps-their-buy-rating-on-turn-therapeutics-inc-ttrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ladenburg-thalmann-co-keeps-their-buy-rating-on-turn-therapeutics-inc-ttrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659885111","title":"Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659885111","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659885111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:39","pubTimestamp":1786567166,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Q2 net loss per share widens on higher R&D costsOverviewUS biotechnology firm's Q2 net loss per share widened yr/yr as R&D expenses increasedCompany expanded GX-03 Phase 2 study afte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44913J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4007","TTRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659021900","title":"Turn Therapeutics Q2 FY26 Net Loss Widens to USD 5.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659021900","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659021900?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:30","pubTimestamp":1786566640,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Q2 FY26 net loss widens to USD 5.85 millionTurn Therapeutics posted a Q2 2026 net loss of $5.85 million, widening from $1.24 million a year earlier.Operating loss widened to $1.63 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLsRJql:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659048900","title":"Turn Therapeutics Q2 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2659048900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659048900?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:30","pubTimestamp":1786566600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXFJFPJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900040","title":"Press Release: Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900040","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900040?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:30","pubTimestamp":1786566600,"startTime":"0","endTime":"0","summary":"Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease ExtentDr.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4139","LENZ","EASI","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654300482","title":"Turn Therapeutics Releases Corporate Deck Outlining GX-03 Topical Immunomodulator Program for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2654300482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654300482?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:09","pubTimestamp":1785240585,"startTime":"0","endTime":"0","summary":"Turn Therapeutics releases corporate deck outlining GX-03 topical immunomodulator program for atopic dermatitisTurn Therapeutics highlighted GX-03, a topical, non-systemic immunomodulator targeting IL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL82rl9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654871004","title":"Turn Therapeutics CEO to Ring NASDAQ Closing Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2654871004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654871004?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:09","pubTimestamp":1785240564,"startTime":"0","endTime":"0","summary":"Turn Therapeutics CEO to ring Nasdaq Closing BellTurn Therapeutics will ring the Nasdaq Closing Bell on Aug. 10, 2026, marking progress since its October 2025 direct listing.CEO Bradley Burnam is scheduled to attend with the management team at Nasdaq MarketSite in Times Square, New York.The Closing Bell broadcast is set to begin at 3:45 p.m. ET.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLSCGkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653719217","title":"Turn Therapeutics Shares Rise on Expanded Phase 2 Study for Eczema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653719217","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653719217?lang=en_us&edition=fundamental","pubTime":"2026-07-21 01:07","pubTimestamp":1784567220,"startTime":"0","endTime":"0","summary":"Turn Therapeutics shares rose after the company said it will add more patients to its Phase 2 study of GX-03, its treatment for atopic dermatitis.Shares were recently up 9.7% at $10.01 in late Monday morning trading after the company said it would expand the study in its second phase. The stock is up about 194% over the past three months.\"The purpose of a staged, adaptive clinical trial is to learn from the first stage to strengthen the second,\" Chief Executive Bradley Burnam said. \"GX-03 demonstrated meaningful activity across a wider spectrum of atopic dermatitis severity than we originally anticipated.\"The company said its expanded study will generate data that could support broader development and future labeling opportunities for GX-03.The program will expand to up to 135 patients from 50 and evaluate patients across the full range of disease severity, as measured by the Eczema Area and Severity Index.The company said enrollment continued during the review, no treatment related se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987886","title":"Turn Therapeutics - Gx-3 Shows Clinically Meaningful Efficacy in Patients with Easi Scores 1.1 to 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987886?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987855","title":"Turn Therapeutics Announces Final Stage 2 Design and Data-driven Expansion of Gx-03 Phase 2 Program in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987855?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982001","title":"Turn Therapeutics - no Treatment-related Serious Adverse Events or Tolerability Issues Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982001?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674308","title":"Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674308","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649674308?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:28","pubTimestamp":1783373280,"startTime":"0","endTime":"0","summary":"Shares of Turn Therapeutics climbed ahead of the company's release of initial findings from a phase 2 trial of GX-03, its treatment for atopic dermatitis.Shares were up 2.9%, to $7.91, in after-hours trading Monday. The stock closed up 8%, at $7.69, having nearly doubled in value this year.The company said Monday that it would present findings from an initial analysis of data from the study on a Tuesday webcast. It would also share an optimized study design for the remaining stage of the phase 2 trial.Write to Elias Schisgall at elias.schisgall@wsj.com Dow Jones NewswiresJuly 06, 2026 17:28 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TTRX","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679923","title":"Turn Therapeutics to Host Webcast on GX-03 Atopic Dermatitis Phase 2 Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679923","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679923?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:01","pubTimestamp":1783368073,"startTime":"0","endTime":"0","summary":"Turn Therapeutics to host webcast on GX-03 atopic dermatitis Phase 2 interim analysisTurn Therapeutics scheduled a live webcast for July 7, 2026, at 4:30 p.m. ET to present interim Phase 2 GX-03 atopi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL6m2zbb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}